Rodman and Renshaw Upgrades Infinity Pharma (INFI) to Market Outperform
More News related to INFI
- Infinity Announces 2009 Financial Results Conference Call
- Infinity Pharma (INFI) Provides FY10 Business and R&D Goals
- Infinity Announces Key 2010 Objectives
- Infinity Announces Updated Presentation Time at the J.P. Morgan Healthcare Conference
- Infinity Announces Presentations at January Conferences
More News related to KOSN
- Rodman and Renshaw Upgrades Infinity Pharma (INFI) to Market Outperform
- Following Today's Kosan (KOSN) Buyout, Investors Look for Next Biotech Deal
- Unusual 11 Mid-Day Movers 5/29: KOSN, ULBI, TRMP, RDEN Higher; ACEL, IFX, SGMO, NM Lower
- Notable Mergers and Acquisitions of the Day 5/29 (BMY/KOSN, TRMP, YHOO/MSFT)
- Pre-Open Movers 5/29: Kosan (KOSN) Surges On Buyback, Evergreen Solar (ESLR) Lower on Downgrade
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Rodman and Renshaw upgrades Infinity Pharmaceuticals Inc. (Nasdaq: INFI) from Market Perform to Market Outperform with a $13 price target, saying the Hsp90 development path is clarifying.
The firm said, "with a Phase III program about to commence, encouraging data from the company's hedgehog inhibitor program, and a valuation well below that of recently-acquired comparable companies Kosan (Nasdaq: KOSN), Serenex, we are raising our investment opinion from Market Perform to Market Outperform."
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
